Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have fail...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lacy, Martha Q., Allred, Jacob B., Gertz, Morie A., Hayman, Suzanne R., Short, Kristen Detweiler, Buadi, Francis, Dispenzieri, Angela, Kumar, Shaji, Greipp, Philip R., Lust, John A., Russell, Stephen J., Dingli, David, Zeldenrust, Steven, Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Stewart, A. Keith, Laumann, Kristina, Mandrekar, Sumithra J., Reeder, Craig, Rajkumar, S. Vincent, Mikhael, Joseph R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291492/
https://ncbi.nlm.nih.gov/pubmed/21690557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-348896
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados